Related Experiment Video
Updated: Aug 5, 2026
Mitochondrial Preparation from Microglia for Glycan Analysis
Published on: May 30, 2025
Targeting Mitochondrial Dysfunction in Microglia: A New Frontier for Treating Neurodegenerative Diseases
Mengqi Chu1, Miaomiao Tan1, Xulin Gan1
1Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Abstract:
Neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) pose an urgent global health challenge. Growing evidence establishes microglia-driven neuroinflammation as a key driver of disease onset and progression, with mitochondrial dysfunction emerging as an early trigger of microglial activation. This review comprehensively summarizes current progress on how mitochondrial alterations regulate microglial activation across AD, PD, and ALS. We identify conserved mechanisms including metabolic reprogramming, impaired mitophagy, and inflammatory signaling, though Aβ, α-synuclein, and TDP-43 engage these pathways through disease-specific molecular routes. Therapeutic strategies targeting microglial mitochondria, including cGAS-STING and NLRP3 inhibitors, TREM2 agonists, and mitochondrial transplantation, remain largely preclinical. Emerging targets such as OLFML3 and GPNMB require functional validation in microglia. Collectively, this review underscores that preserving microglial mitochondrial health represents a promising therapeutic frontier and identifies key priorities for translating these strategies toward clinical application.
Insights
Mitochondrial dysfunction in microglia drives neuroinflammation in Alzheimer's, Parkinson's, and ALS. Preserving microglial mitochondrial health offers a promising therapeutic avenue for these neurodegenerative diseases.
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Neurodegenerative diseases like Alzheimer's (AD), Parkinson's (PD), and ALS are significant health concerns.
- Microglia-driven neuroinflammation and mitochondrial dysfunction are key factors in disease initiation and progression.
Purpose of the Study:
- To review how mitochondrial alterations regulate microglial activation in AD, PD, and ALS.
- To identify conserved and disease-specific mechanisms linking mitochondrial health to neuroinflammation.
Main Methods:
- Comprehensive literature review of studies on microglial mitochondria in neurodegenerative diseases.
- Analysis of conserved pathways such as metabolic reprogramming and mitophagy.
- Examination of disease-specific molecular triggers like Aβ, α-synuclein, and TDP-43.
Main Results:
- Conserved mechanisms including metabolic reprogramming, impaired mitophagy, and inflammatory signaling are regulated by mitochondrial alterations.
- Disease-specific molecules engage these pathways differently across AD, PD, and ALS.
- Current therapeutic strategies targeting microglial mitochondria are mostly preclinical, with some emerging targets needing validation.
Conclusions:
- Preserving microglial mitochondrial health is a promising therapeutic strategy for neurodegenerative diseases.
- Further research and validation are needed to translate preclinical findings into clinical applications.
- Targeting microglial mitochondrial pathways offers a novel frontier for treating AD, PD, and ALS.
